A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder

Sushmitha S. Purushotham,Neeharika M. N. Reddy,Michelle Ninochka D’Souza,Nilpawan Roy Choudhury,Anusa Ganguly,Niharika Gopalakrishna,Ravi Muddashetty,James P. Clement
DOI: https://doi.org/10.1007/s00221-022-06448-x
2022-09-06
Experimental Brain Research
Abstract:Intellectual disability (ID) and autism spectrum disorder (ASD) are neurodevelopmental disorders that have become a primary clinical and social concern, with a prevalence of 2–3% in the population. Neuronal function and behaviour undergo significant malleability during the critical period of development that is found to be impaired in ID/ASD. Human genome sequencing studies have revealed many genetic variations associated with ASD/ID that are further verified by many approaches, including many mouse and other models. These models have facilitated the identification of fundamental mechanisms underlying the pathogenesis of ASD/ID, and several studies have proposed converging molecular pathways in ASD/ID. However, linking the mechanisms of the pathogenic genes and their molecular characteristics that lead to ID/ASD has progressed slowly, hampering the development of potential therapeutic strategies. This review discusses the possibility of recognising the common molecular causes for most ASD/ID based on studies from the available models that may enable a better therapeutic strategy to treat ID/ASD. We also reviewed the potential biomarkers to detect ASD/ID at early stages that may aid in diagnosis and initiating medical treatment, the concerns with drug failure in clinical trials, and developing therapeutic strategies that can be applied beyond a particular mutation associated with ASD/ID.
neurosciences
What problem does this paper attempt to address?